EUCTR2011-004653-31-ES进行中（未招募）不适用
A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-?2a and ribavirin (peg-IFN?2a/RBV) in protease inhibitor treatment failure patients with chronic hepatitis C genotype 1
ovartis Farmacéutica S.A0 个研究点目标入组 173 人开始时间: 2012年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 173
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. HCV GT1 patients with previous PI treatment failure. 2. Timing of the PI treatment. the minimum time from the last dose of previous PI treatment to the first dose of study medication is three months. 3. Diagnosed Chronic hepatitis C virus infection 4. Infection with HCV genotype 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 44
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 44
排除标准
- •1. Use of other investigational drugs at the time of enrollment, 2. History of hypersensitivity to any pegIFN or RBV. 3. Any null non-responders to prior pegIFN/RBV treatment, Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
进行中（未招募）
不适用
Alisporivir con pegIFN / RBV in pazienti con epatite C cronica con precedente fallimento terapeutico all'inibitore della proteasiEUCTR2011-004653-31-ITOVARTIS FARMA173
进行中（未招募）
不适用
Alisporivir with pegIFN/RBV in protease inhibitor (PI) treatment failure patients with chronic hepatitis CEUCTR2011-004653-31-DEovartis Pharma Services AG173
进行中（未招募）
不适用
Alisporivir with pegIFN/RBV in protease inhibitor (PI) treatment failure patients with chronic hepatitis CEUCTR2011-004653-31-GBovartis Pharma Services AG173
进行中（未招募）
2 期
A multicentre single arm study of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (MM) patients refractory to initial bortezomib-based induction therapyCancer - MyelomaMultiple MyelomaACTRN12615000934549Australiasian Leukaemia and Lymphoma Group50
尚未招募
Unknown
A single-center clinical study to evaluate the safety and efficacy of autologous bone marrow-derived DCs(CellgramDC-WT1) and immune checkpoint inhibitors in patients with metastatic pancreatic cancer who have failed first-line or more standard chemotherapyKCT0009102Soon Chun Hyang University Hospital Seoul10